Natalizumab: increased vigilance is required in treating patients with multiple sclerosis

Hasan, S.K. , Mays, A.N. , Ottone, T. , Ledda, A. , La Nasa, G. , Cattaneo, C. et al. (2008) Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, June 23, e-pub ahead of print.

Hemmer, B. , Frohman, E. , Hartung, H.P. and Stuve, O. (2006) Central nervous system infections - a potential complication of systemic immunotherapy. Curr Opin Neurol 19(3): 271-276.

Mock, D.J. , Powers, J.M. , Goodman, A.D. , Blumenthal, S.R. , Ergin, N. , Baker, J.V. et al. (1999) Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. J Neurovirol 5(4): 363-373.

Mullen, J.T. , Vartanian, T.K. and Atkins, M.B. (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358(6): 647-648.

Saccardi, R. , Tyndall, A. , Coghlan, G. , Denton, C. , Edan, G. , Emdin, M. et al. (2004) Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant 34(10): 877-881.

Stuve, O. , Marra, C.M. , Bar-Or, A. , Niino, M. , Cravens, P.D. , Cepok, S. et al. (2006a) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63(10): 1383-1387.

Stuve, O. , Marra, C.M. , Jerome, K.R. , Cook, L. , Cravens, P.D. , Cepok, S. et al. (2006b) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59(5): 743-747.

Yao, K. , Gagnon, S. , Akhyani, N. , Williams, E. , Fotheringham, J. , Frohman, E. et al. (2008) Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 3(4): e2028.